Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 May 2013Website:
http://arcturusrx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 21:06:58 GMTDividend
Analysts recommendations
Institutional Ownership
ARCT Latest News
Arcturus is a top pick in the biotech sector with a strong stock market performance. The company generates revenue from research and development partnerships, which helps conserve cash. The launch of the Kostaive vaccine and other programs are expected to drive revenue growth in the short and long term.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference i.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic t.
Arcturus Therapeutics (ARCT) lacks the necessary elements for a potential earnings beat in its upcoming report. Make sure to be aware of the key expectations.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President & Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer & Chief Operating Officer Conference Call Participants Evan Wang - Guggenheim Securities Whitney Ijem - Canaccord Genuity Myles Minter - William Blair Jan Hughes - Wells Fargo Pete Stavropoulos - Cantor Fitzgerald Thomas Yip - H.C.
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $1.69. This compares to earnings of $4.33 per share a year ago.
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
We've all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives.
Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing therapies for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis. Despite trading at a slight premium relative to peers, ARCT's investment appeal is supported by its innovative IP, financial health, and clinical trials.
- 1(current)
- 2
What type of business is Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings, Inc. is a pharmaceutical company specializing in the development of drugs for the treatment of liver and respiratory diseases. The company was founded in 2013 with headquarters in San Diego, California. Arcturus Therapeutics is involved in the discovery and development of RNA-based drugs, including the production of RNA drug substance and drug product in nanoparticle form, as well as the development of vaccines against infectious diseases using self-transcribing and replicating RNA (STARR) technology. The company has several preclinical programs, including the LUNAR-OTC program, which is developing mRNA compounds for the treatment of ornithine transcarbamylase (OTC) deficiency, the LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis patients, as well as LUNAR-CV and LUNAR-MD programs.
What sector is Arcturus Therapeutics Holdings in?
Arcturus Therapeutics Holdings is in the Healthcare sector
What industry is Arcturus Therapeutics Holdings in?
Arcturus Therapeutics Holdings is in the Biotechnology industry
What country is Arcturus Therapeutics Holdings from?
Arcturus Therapeutics Holdings is headquartered in United States
When did Arcturus Therapeutics Holdings go public?
Arcturus Therapeutics Holdings initial public offering (IPO) was on 22 May 2013
What is Arcturus Therapeutics Holdings website?
https://arcturusrx.com
Is Arcturus Therapeutics Holdings in the S&P 500?
No, Arcturus Therapeutics Holdings is not included in the S&P 500 index
Is Arcturus Therapeutics Holdings in the NASDAQ 100?
No, Arcturus Therapeutics Holdings is not included in the NASDAQ 100 index
Is Arcturus Therapeutics Holdings in the Dow Jones?
No, Arcturus Therapeutics Holdings is not included in the Dow Jones index
When does Arcturus Therapeutics Holdings report earnings?
The next expected earnings date for Arcturus Therapeutics Holdings is 07 August 2024